Ekso Bionics Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Acquisition (Tables)

Acquisition (Tables)

12 Months Ended

Dec. 31, 2015

The total purchase price is summarized as follows:

	Amount
Stock consideration (781 shares)	$	1,071
Estimated contingent consideration		768
Total purchase price	$	1,839

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes the preliminary estimated fair values of the assets acquired as of the acquisition date:

	Amount
Fixed assets	$	40
Intangible assets		1,610
Total identifiable assets acquired		1,650
Goodwill		189
Net assets acquired	$	1,839

Schedule of Acquired Indefinite-lived Intangible Assets by Major Class

Acquired intangible assets as of December 31, 2015 were as follows:

	Gross Amount		Accumulated Amortization		Net Carry Amount		Estimated Useful Life
Developed technology	$	1,160	$	19	$	1,141		3 yrs
Customer relationships		70		1		69		3 yrs
Customer trade name		380		6		374		3 yrs
	$	1,610	$	26	$	1,584

Business Acquisition, Pro Forma Information

The following unaudited pro forma financial information reflects the Company’s consolidated statement of operations as if the acquisition of Equipois had taken place on January 1, 2014. The pro forma information includes adjustments for royalty revenue, impact from the Supply Agreement, and the amortization of intangible assets. The pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transaction been effected on the assumed date.

	Years Ended December 31
	2015		2014
Revenue	$	9,434	$	5,449
Net loss	$	(19,590)	$	(33,978)